Obesity and associated metabolic diseases are characterized by a chronic low-grade inflammatory state with the infiltration of many inflammatory cells, especially macrophages. Immune molecules, including some cytokines, have a close relationship with metabolism. Interleukin (IL)-25 is a member of the IL-17 cytokine family that can regulate macrophages and alleviate some metabolic dysfunction; however, its role and mechanisms in lipid metabolism remain to be extensively clarified. Human serum and liver biopsy specimens, high-fat diet-induced obesity mice and DB/DB (Lepr − / − ) animal models were used to examine IL-25 expression in obesity and nonalcoholic fatty liver diseases (NAFLD). To observe the role of IL-25 in lipid metabolism, model mice were administered with IL-25 or adoptively transferred with IL-25-educated macrophages in vivo, whereas bone marrow-derived macrophages, the macrophage cell line RAW264.7 and adipocytes differentiated from 3T3-L1 were used in vitro. IL-25 was decreased in NAFLD patients and obese mice. In addition, IL-25 reduced body weight gain and lipid accumulation, enhanced lipid uptake by macrophages and increased the expression of lipolysis and β-oxidation enzymes via alternatively activating macrophages. IL-25 also promoted lipolysis and suppressed lipogenesis in adipocytes co-cultured with the IL-25-educated macrophages. Furthermore, IL-25 improved the mitochondrial respiratory capacity and oxygen consumption rate of macrophages and produced more NAD + /NADH and ATP. In conclusion, IL-25 can stimulate M2 macrophage polarization and thereby promote lipolysis and mitochondrial respiratory capacity, highlighting the potential for IL-25 to be used as a therapeutic agent against obesity and associated metabolic syndromes.
INTRODUCTION
Obesity is an emerging public health problem worldwide. According to the World Health Organization, more than 39% of adults are overweight, and~13% were clinically obese in 2014. 1, 2 Obesity is related to many diseases, such as nonalcoholic fatty liver disease (NAFLD), insulin resistance, cardiovascular diseases and some endocrine diseases. [3] [4] [5] Obesity is a risk factor not only for metabolic diseases but also for pulmonary diseases and cancer. 6, 7 Therefore, it is urgent to seek appropriate therapeutic and preventive measures for obesity and its complications.
Metabolic diseases, such as obesity and diabetes, are well known to be related to overnutrition and a sedentary lifestyle, and they are also regarded as an immune imbalance between type-1 and type-2 immunity because these metabolic diseases are usually characterized by chronic low-grade systemic inflammation. Inflammatory factors, including cytokines, and mediators may be the causative factors of many metabolic 1 disorders, such as diabetes, obesity and insulin resistance. 8 Adipose tissue has long been considered an energy-storage organ, whereas it is increasingly accepted that adipose tissue is an endocrine organ that can secrete several types of hormones and cytokines. [9] [10] [11] Immune cells, such as macrophages, in adipose tissue are important to maintain the adipose tissue homeostasis and regulate body weight. 12 Typically, accumulated macrophages in adipose tissue are closely associated with systemic low-grade inflammation, obesity-linked liver damage and insulin resistance. 13 Macrophages are mainly classified into two phenotypes, namely classically activated macrophages (M1), which predominantly produce inflammatory factors, and alternatively activated macrophages (M2), which mainly generate anti-inflammatory factors. Macrophage accumulation in adipose tissue is increased in obese people and animals, and obesity can promote the accumulation of pro-inflammatory M1 macrophages in adipose tissue. 12, 14 Adipocytes, especially adipose tissue-derived stem cells from obese but not lean subjects promote Th17 differentiation and activation, 15 and, in turn, interleukin (IL)-17 can inhibit adipogenesis. 16 IL-25, also called IL-17E, is a member of the IL-17 family, which includes IL-17A to IL-17F. [17] [18] [19] [20] IL-25 participates in Th2-type anti-inflammatory responses, which are associated with some immune diseases, such as asthma and allergic inflammation. 18, 20 IL-25 is also considered to be a potential therapeutic agent for hepatic steatosis and fulminant hepatitis. 21, 22 Compared with wild-type mice, enlarged livers and increased body weight were observed in IL-25 knockout mice. 21 IL-25 can reduce body weight and improve glucose tolerance with the increased infiltration of innate lymphoid type-2 cells and type I and type II NKT cells in visceral adipose tissue. 23 However, the role and mechanism of IL-25-and IL-25-stimulated macrophages in fat metabolism remain to be elucidated. In the present study, we examined the expression level of IL-25 in metabolic diseases, investigated the role of IL-25 in macrophage polarization and consequent lipid metabolism, elucidated the metabolic mechanism of IL-25-triggered lipolysis and provided evidence of IL-25 as a factor in immunometabolism against obesity.
MATERIALS AND METHODS

Ethics statement
All the animal experiments were conducted with the approval of the Animal Care and Use Committee of Sun Yat-sen University (Approval ID: SCXK2011-0029). The clinical investigation complied with the ethical principles established by the 1964 Declaration of Helsinki. The sample collection from patients was approved by the Ethics Committee of the Guangzhou Women and Children's Hospital and the First Affiliated Hospital of Sun Yat-sen University. All the patients or family members involved provided written informed consent. Animals C57BL/6 wild-type mice were purchased from the Laboratory Animal Center of Sun Yat-sen University (Guangzhou, China). The care, use and treatment of all animals in this study were in strict accordance with the principles set forth by the Animal Care and Use Committees of Sun Yat-sen University. For these experiments, 4-to 5-week-old male mice were fed a normal chow diet (NCD) or a high-fat diet (HFD, 60% of calories, D12492, Research Diets Inc., NJ, USA) for 3 months to create the obesity model, and body weight and food consumption were monitored. At the end of 3 months of the NCD or HFDinduction program, mice were intraperitoneally injected with bovine serum albumin (BSA) or IL-25 (1 μg in 100 μl phosphate-buffered saline (PBS) for each mouse, Biolegend, San Diego, CA, USA) every day for 7 days followed by every other day for an additional 16 days for a total of 23 days. During the HFD treatment, the serum and tissues of mice were also collected at 0, 1, 2, 4, 12 and 16 weeks to explore changes in the level of IL-25. DB/DB (Lepr − / − ) mice were purchased from the Nanjing Laboratory Animal Center (Nanjing, China).
Macrophage culture, adoptive transfer Bone marrow-derived macrophages (BMMCs) were generated as previously described. 24 Briefly, mononuclear cells were flushed from the femurs and tibias of C57BL/6 mice and cultured overnight. The non-adherent cells were collected and centrifuged at 1200 r.p.m. for 10 min. The cells were then treated with Red Cell Lysis Buffer (Sigma-Aldrich, St Louis, MO, USA). Mature macrophages were obtained from the differentiated mononuclear cells and stimulated with 20 ng/ml macrophage colony-stimulating factor (Biolegend, #576406) for 7 days. Mouse RAW264.7 macrophages were from the American Type Culture Collection (ATCC, Manassas, VA, USA). BMMCs and mouse RAW264.7 macrophages were cultured in dulbecco's modified eagle medium with 10% fetal bovine serum (Gibco by Life Technologies, Bleiswijk, the Netherlands) and 1% penicillin/streptomycin. Cells were cultured at 37°C with 5% CO 2 . For adoptive transfer, BMMCs stimulated with or without IL-25 (50 ng/ml, Biolegend, #587306), IL-15 (25 ng/ml, Biolegend) and interferon gamma (IFNγ; 50 ng/ml, Biolegend) for 2 days were collected in cold PBS, and 1 × 10 6 cells were adoptively transferred into every mouse intraperitoneally after a HFD for 3 months. The adoptive transfer was performed two times interspaced for a week, and all mice were killed for analysis 7 days after the second adoptive transfer experiment.
Co-culture of macrophages and adipocytes Confluent 3T3-L1 (ATCC) cells seeded in six-well plates were induced into mature adipocytes with 0.5 mM isobutylmethylxanthine (Sigma-Aldrich), 1 μM dexamethasone (SigmaAldrich) and 10 μg/ml insulin (Sigma-Aldrich) in dulbecco's modified eagle medium containing 10% fetal bovine serum for 2 days and then treated with dulbecco's modified eagle medium containing 10 μg/ml insulin and 10% fetal bovine serum for 7 days. Then, 3 × 10 5 RAW264.7 cells/well were seeded into Transwell chambers (Corning, New York, NY, USA) on top of the mature adipocytes for 2 days. Different cytokines, such as IL-5 (50 ng/ml, Biolegend), IL-15 (25 ng/ml, Biolegend), IL-25 (50 ng/ml, Biolegend), IFNγ (50 ng/ml, Biolegend) and lipopolysaccharide (LPS; 10 ng/ml, Sigma), were administered for treatment of the macrophages.
RNA Extraction and Quantitative Real-Time PCR Total RNA was extracted from tissues or cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). In total, 1000 ng total RNAs were reverse-transcribed to complementary DNA (cDNA) using the Prime Script RT Reagent Kit Perfect Real-Time Kit (TaKaRa Bio Inc., Kusatsu, Shiga, Japan). The cDNA was then used for quantitative real-time PCR (qPCR) using SYBR Premix Ex Taq (TaKaRa Bio Inc.). 25 The expression of the target mRNA was determined using the comparative cycle threshold method normalized to the 18S gene as previously described. 26 The primers used for the qPCR are listed in Supplementary Table 1 .
Oil Red O Staining
The slices were fixed with 4% paraformaldehyde. After fixation, lipid droplets of tissue slices were stained with Oil Red O prepared in 2-propanol (0.5%) as the stock solution, and the working resolution was freshly diluted with distilled deionized water. The slices were incubated with the Oil Red O working solution (60 ml stock solution mixed with 40 ml deionized water) for 15 min and stained with hematoxylin for 30 s. All the slices were observed under a light contrast microscope.
Western blotting
Cells were harvested and lysed for preparation. The protein concentration was determined using the KeyGen Protein Assay Kit (KeyGen, Nanjing, Jiangsu, China) according to the manufacturer's instructions. Equal amounts of protein extracts were subjected to a western blot analysis. The proteins transferred to the polyvinylidene fluoride membrane (Millipore, Boston, MA, USA) were probed with primary antibodies specific for adipose triglyceride lipase (ATGL; 1:1000; Cayman Chemical Co., Madison, MI, USA, #10006409), p-ACC (1:1000; Cell Signaling Technology, Danvers, MA, USA, #3661S), ACC (1:1000; CST, #3676S), monoacylglycerol Lipase (MAGL) (1:1000; Cayman Chemical Co., #100035), phosphorylated hormone sensitive lipase (p-HSL) (1:1000; Abcam, Cambridge, MA, USA, #ab109400), hormone sensitive lipase (HSL) (1:1000; CST, #18381S), CPT1α (1:1000; Proteintech Group, Chicago, IL, USA, #15184-1-AP) and β-actin (1:10000, Sigma-Aldrich, #A5441) overnight at 4°C. The membranes were then washed with TBST and incubated with peroxidaseconjugated secondary antibodies at 4°C for 3 h. The following secondary antibodies were used: goat anti-rabbit IgG/HRP (1:1000; Vector Laboratories, Youngstown, OH, USA, #PI1000) and goat anti-mouse IgG/HRP (1:1000; Vector Laboratories, Youngstown, OH, USA, #PI2000). Chemiluminescence was developed using ECL western blotting substrate and quantified using the ImageJ software (NIH, Bethesda, MD, USA).
ELISA of IL-25 in human liver biopsy specimens and mouse tissues Biopsies of liver sections and serum were acquired from a total of 14 patients. Six of these patients had hepatic steatosis, initially diagnosed with an ultrasound examination and later confirmed by a liver biopsy evaluation. The other eight patients had no hepatic steatosis and were used as controls. Their medical histories were reviewed retrospectively by a medical doctor that specializes in gastroenterology and hepatology. All the patients were 418 years old at the time of biopsy and had no history of alcohol abuse, serologic evidence of viral hepatitis, blood transfusions or history of other competing etiologies for hepatic steatosis and coexisting causes for chronic liver disease. 27 For the sample preparation of tissues, liver or epididymal white adipose tissues (eWAT) were homogenized in ice-cold PBS with a protease inhibitor cocktail, followed by centrifugation at 1500g for 10 min. Then, the supernatants were collected for the enzyme-linked immunosorbent assay (ELISA), and the protein concentration was measured using the KeyGen protein assay kit (KeyGen). The expression levels of IL-25 in the cell supernatant, serum and tissues were detected using the Mouse IL-25 ELISA Kit (Biolegend, #434004) or the human IL-25 ELISA Kit (Cloud-Clone Corp., #SEB694Hu) according to the manufacturer's instructions. Measurement of triglycerides, free fatty acids, HDL, LDL/VLDL, ATP and NAD + /NADH The triglycerides (TGs) and free fatty acids (FFAs) in the tissues and plasma were measured using the EnzyChrom Triglyceride Assay Kit (BioAssay Systems, Hayward, CA, USA, Cat# ETGA-200) and EnzyChrom Free Fatty Acid Assay Kit (BioAssay Systems, Hayward, CA, USA, Cat#EFFA-100) according to the manufacturer's instructions. In addition, the levels of high-density lipoprotein (HDL) and low-density lipoprotein/very low-density lipoprotein (LDL/VLDL) in the serum were also measured using the EnzyChrom AF HDL) and (LDL /VLDL) Assay Kit (BioAssay Systems, Hayward, CA, USA, E2HL-100) according to the manufacturer's instructions. The ATP and NAD + /NADH produced by RAW264.7 macrophages or BMMC were measured with the ATP detection kit (Beyotime Biotechnology, Beyotime Institute of Biotechnology, Haimen, Jiangsu, China, #S0026) and NAD + /NADH Quantification Colorimetric Kit (Biovision, San Francisco, CA, USA, #K337-100) according to the manufacturer's instructions.
Immunofluorescence staining
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MitoTracker staining BMMC and RAW264.7 macrophages were incubated with 100 nM MitoTracker Green FM (Life Technologies, #M7514) for 30 min according to the manufacturer's instructions. Then, the cells were washed with PBS and visualized under a confocal microscope.
Adipocyte area quantification eWAT sections were hematoxylin and eosin-stained and imaged at × 40 magnification. The adipocyte size was analyzed using the ImageJ software via drawing ellipses circumscribing white adipocytes. Two to three images and 15-20 adipocytes per image were measured. 28 Measurement of oxygen consumption rate The oxygen consumption rate was measured with a Seahorse Bioscience XF-96 extracellular flux analyzer (Seahorse Bioscience) according to the manufacturer's instructions as detailed elsewhere. [29] [30] [31] Cells stimulated with different cytokines were seeded in XF 24-well plate (Seahorse Bioscience, North Billerica, MA, USA) with Seahorse XF medium supplemented with 10 mM glucose, 1 mM sodium pyruvate and 2 mM glutamine. The plate was pretreated under a non-CO 2 condition for 1 h, sequentially injected with oligomycin (inhibition of ATP synthase), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, (uncoupling agent of oxygen consumption from ATP production) and rotenone and antimycin A (inhibitor of complex I and III in the electron transport chain of mitochondria) into each well, and then processed in the XF analyzer for the oxygen consumption rate (OCR) measurement and analysis. The compounds listed above were sequentially injected into each well to measure ATP production, maximal respiration and non-mitochondrial respiration.
Data analysis
All the data are expressed as the mean ± s.d. Student's t-test was applied for comparisons between two groups, and one-way analysis of variance followed by least significant difference t-test was used for comparisons of more than two different groups (GraphPad Prism software, GraphPad Software, San Diego, CA, USA). A P-value less than 0.05 was considered statistically significant.
RESULTS
IL-25 correlated with body mass index and decreased in liver and eWAT
We examined the levels of IL-25 in the serum and liver biopsy samples from patients with or without NAFLD. IL-25 expression was decreased in the serum and liver of NAFLD patients who had a higher BMI, body mass index (BMI; Figures 1a and b) . To further investigate the role of IL-25 in NAFLD, we established a diet-induced obesity (DIO) mouse model with hepatic steatosis. During the HFD treatment, the levels of IL-25 in the serum (Figure 1c ) and liver ( Figure 1d) were reduced from the second week of the HFD program. In the DIO animal model, both the mRNA and protein levels of IL-25 were reduced in the HFD-fed mice compared with those in the NCD-fed mice both in eWAT ( Figure 1f ) and liver ( Figure 1e ). We also observed the expression of IL-25 in the liver and eWAT of DB/DB (Lepr − / − ) obese mice. The results were similar to those in the DIO mice; there was reduced expression of IL-25 in the liver and eWAT of DB/DB obese mice (Supplementary Figure S1) . Therefore, IL-25 may correlate with obesity and associated metabolic diseases.
IL-25 administration reduced body weight gain and lipid accumulation without affecting food intake via the alteration of metabolic enzymes in vivo To further investigate the metabolic role of IL-25 in lipogenesis or lipolysis during obesity, exogenous IL-25 was administered to HFD-fed obese mice at the end of the HFD-induction program. Mice fed with an NCD or an HFD for 3 months were administered BSA or IL-25 (1 μg in 100 μl PBS for each mouse) every day for 7 days, followed by every other day for an additional 16 days for a total of 23 days. IL-25 decreased body weight gain and fat mass in the HFDfed mice (Supplementary Figures S2B and C) without affecting food intake (data not shown). The adipocyte size of eWAT was decreased in the HFD-fed mice treated with IL-25 ( Figure 2d ). IL-25 also decreased the liver mass of the HFD-fed mice (Supplementary Figure S2D) , reduced lipid accumulation and alleviated hepatic steatosis in the liver (Figure 2g) . Moreover, IL-25 promoted fat mobilization and lipolysis in the HFD-fed mice, with a decrease in TGs and an increase in FFA in the serum (Figure 2a) , eWAT ( Figure 2e ) and liver (Figure 2h ). In addition, the IL-25 administration increased the level of HDL, which is a protective lipoprotein against cardiovascular diseases, and decreased the level of LDL/VLDL, which is a risk factor for cardiovascular diseases, in the serum of the HFD-fed obese mice (Figure 2a) . In eWAT and liver, fat mobilization was mediated by ATGL, which was decreased in the HFD-fed mice but increased during the treatment with IL-25 (Figures 2b and c) . Although the mRNA of lipogenic enzymes, including Acly and Acaca, was not significantly varied, the mRNA of lipolytic enzymes such as Atgl, enzymes for long-chain acyl-CoA (or FFA) penetrating the membrane of mitochondria such as carnitine palmitoyltransferase-Ⅰ(Cpt1α), and enzymes for β-oxidation such as hydroxyacyl-coenzyme A dehydrogenase (Hadh), were significantly upregulated during the treatment with IL-25 in eWAT (Figure 2f) . Similar results were observed in the liver (Figure 2i) . Consequently, the lipolytic effect of IL-25 may be associated with its regulation of some lipid metabolic enzymes. Furthermore, the expression levels of M2 markers (ARG1) and transcription factor (IRF4) were increased during the treatment with IL-25 in a concentration-dependent manner, whereas the expression of M1 transcription factor (IRF5) was not significantly varied ( Supplementary Figures S3A-C) . Therefore, IL-25 stimulated M2 polarization of macrophages both in vivo and in vitro. With the polarization of macrophages and changes in the cytokine profiles, the function and metabolic characteristics of macrophages were also switched.
IL-25 increased lipid uptake and enhanced lipolysis via macrophages IL-25 participates in immune metabolism via regulating the phenotype and functions of macrophages. RAW264.7 macrophages and differentiated 3T3-L1 adipocytes were either directly stimulated with IL-25 and a type-1 cytokine (IFNγ) or a mediator (LPS) or were co-cultured together using a uptake by macrophages and decreased lipid droplet accumulation in adipocytes in a concentration-dependent manner (Supplementary Figures S4A-C) .
IL-25 increased the mitochondrial respiratory capacity as indicated by the increased expression of CPT1ɑ, NAD + /NADH production, ATP production and OCR in macrophages According to the theory of energy metabolism, mitochondrial respiratory capacity and energy metabolism are also crucial for the occurrence and development of obesity. As CPT1ɑ is a key enzyme participating in β-oxidation of fatty acids in the mitochondria, we explored its expression in macrophages stimulated with cytokines. IL-25 increased the expression of CPT1ɑ in macrophages (Figure 5a ), which meant that IL-25 may transfer more fatty acids to the mitochondria for oxidation. As shown by the MitoTracker staining results, IL-25 amplified the mass of the mitochondria and promoted its infusion (Figure 5d ), which indicated that IL-25 may improve mitochondrial respiratory capacity. IL-25 promoted total NAD + (NADt) or NADH production in macrophages (Figures 5b and c) , which reflected greater potential energy via the respiratory chain. Finally, IL-25 increased the oxygen consumption rate (Figure 5f ) and ATP production (Figure 5e ) of the macrophages versus the control group, indicating that IL-25 may promote the aerobic oxidation and energy (Figure 6a ) and increased Atgl mRNA (Figure 6c ), which had an important role in lipolysis. In addition, the adoptive transfer of Mø-IL-25 increased Cpt1ɑ mRNA in the HFD-fed mice to promote lipid transportation to the mitochondria and β-oxidation to some extent (Figure 6e ). Whereas the role of Mø-IL-15 and Mø-IFNγ was not obvious in these above-mentioned aspects, Mø-IL-25, Mø-IL-15 and Mø-IFNγ also decreased the expression of Cidea to promote lipolysis (Figure 6f ), whereas the expression of Cd36, which participates in fatty-acid uptake (Figure 6d) , was increased. Mø-IL-25 also increased the level of HDL and decreased the level of LDL/VLDL (Figure 6b ), which may be helpful for cardiovascular diseases. 
DISCUSSION
This study showed that IL-25 expression was reduced in NAFLD patients and a mouse model of obesity with greater lipid accumulation. The results indicate that IL-25 may be associated with obesity and lipid metabolism. We further found that the administration of exogenous IL-25 reduced body weight gain and the mass of both eWAT and liver in HFDfed mice. Both the adipocyte size of eWAT and lipid accumulation in the liver were reduced in the HFD-fed mice after the IL-25 treatment. The results indicated that IL-25 promoted lipid metabolism. The protective effect of IL-25 on hepatic steatosis was in accordance with the results previously reported. 21 As macrophages accumulate in adipose tissue, we further explored the potential role of IL-25-triggered and macrophage-mediated immunometabolism in this system. IL-25 is a member of the IL-17 family, which participates in anti-inflammatory responses. 32 IL-25 targets macrophages to induce type-2 immunity. 24 In our study, we identified that IL-25-stimulated macrophages expressed more M2 markers and cytokines in vitro. In vivo, there were more ARG1 and F4/80 double-positive cells accumulated in both the liver and eWAT of IL-25-treated HFD-fed mice. Therefore, IL-25 promoted the M2 polarization of macrophages. M2 macrophages may prefer the β-oxidation of fatty acids as fuel to produce energy and metabolites. 33, 34 Our results indicated that IL-25 promoted lipid metabolism via M2 polarization of macrophages.
In our study, we further explored the metabolic characteristics of macrophages stimulated with IL-25. In macrophages, IL-25 enhanced the expression of lipolytic enzymes (ATGL, MAGL and p-HSL), decreased the expression of the lipogenic enzyme FAS and inhibited the activity of the lipogenic enzyme ACC by increasing its phosphorylation as the phosphorylated form of ACC is inactive. It is known that ATGL and HSL are IL-25 against obesity via polarization of macrophages J Feng et al the rate-limiting enzymes that hydrolyze stored esters to FFAs. 35, 36 ATGL, which is expressed predominantly in adipose tissue, is also found to hydrolyze intracellular TGs into FFAs within cardiac and skeletal muscle. 35 HSL, which is expressed not only in adipose tissue but also in steroidogenesis tissue such as testis, hydrolyzes stored TGs or cholesteryl esters to FFAs. 36, 37 FAS is a multienzyme that catalyzes fatty-acid synthesis, and ACC is the rate-limiting enzyme participating in the first step of fatty-acid synthesis. Consequently, the more lipids that macrophages engulf, the more lipolysis that occurs under an IL-25 challenge. After releasing more FFAs, IL-25 significantly promoted the transportation and oxidation of FFA. It was interesting that the mRNA expression of lipolytic enzyme genes such as Cpt1ɑ, Hadh and Atgl increased, but expression did not increase for the lipogenic enzyme genes, such as Acly and Acaca. CPT1ɑ is responsible for transferring long-chain fatty acids into the mitochondria for β-oxidation. With the regulation of lipid metabolism enzymes, the lipolysis ability of macrophages was enhanced. Moreover, we observed that IL-25 amplified the mitochondrial capacity and promoted mitochondrial infusion, as shown by the MitoTracker staining. It indicated that IL-25 may influence β-oxidation and energy 25 . These results suggested that IL-25 influences the metabolic characteristics of macrophages and adipocytes. IFNγ and LPS were used as type-1 immune response controls, and they are typical type-1 cytokines or mediators for the classical activation of macrophages. It seems that the expression of p-HSL, ATGL and MAGL increased in 3T3-L1 adipocytes co-cultured with macrophages stimulated with IL-25 or IFNγ compared with the Veh group, whereas IL-25 largely increased the p-ACC level compared with the Veh group and the groups treated with the other two cytokines (IFNγ and LPS; Figure 4e ). In macrophages, IL-25 increased the levels of p-ACC, ATGL and p-HSL more (Figure 4b ) than that in the Veh group and the groups treated with the other two cytokines. Thus, we should consider the integrated effects of IL-25 on lipolysis in many aspects altogether, such as the effects of IL-25 on macrophages, adipocytes and their interaction. It has been reported that IL-33, another type-2 cytokine, also diminished lipid accumulation and delayed adipocyte differentiation. 40 Furthermore, the adoptive transfer of Mø-IL-25 into HFD-fed mice also had similar effects, such as decreasing the level of serum lipids, increasing the expression of Atgl and Cpt1ɑ, the hydrolysis of TG and the transportation of FFA to the mitochondria for β-oxidation.
It seems paradoxical to compare the level of FFA between HFD-IL-25 treatment and the adoptive transfer of HFD-Mø-IL-25. However, they are two different experiments that have the following two major differences: one focuses on the uptake of FFA, and the other addresses the transportation of FFA across the mitochondrial membrane for β-oxidation. Our data demonstrated that the adoptive transfer of macrophages treated by IL-25 resulted in the macrophages engulfing more FFA (Figure 4a and Supplementary Figure S4) . The adoptive transfer also enhanced the level of CPT1α to a level greater than that achieved by the IL-25 injection as the IL-25 injection directly increased CPT1α by approximately twofold (Figure 2f) . The adoptive transfer of macrophages treated with IL-25 increased the level of CPT1α by approximately sevenfold (Figure 6f ). Consequently, IL-25 may regulate enzymes related to the promotion of lipolysis and the inhibition of lipogenesis both in macrophages and adipocytes.
In conclusion, IL-25 promotes lipid metabolism and energy production, improves mitochondrial respiratory capacity and alleviates lipid accumulation in the liver and adipose tissues via alternatively activated macrophages and its interaction with adipocytes ( Figure 7) . Moreover, the administration of IL-25 reduces obese body weight gain, alleviates hepatic steatosis and regulates enzymes involved in lipid metabolism. The role of IL-25 in immunometabolism may contribute to ameliorating metabolic dysfunction in obesity.
